Immunotherapy for colorectal cancer

Patrick M. Boland, Wen Wee Ma

Research output: Contribution to journalReview articlepeer-review

79 Scopus citations


The recent success of anti-PD1 drugs in metastatic colorectal cancer patients with mismatch repair deficiency generated overwhelming enthusiasm for immunotherapy in the disease. However, patients with mismatch repair deficient colorectal cancer represent only a small subset of the metastatic population. Current research focuses on advancing immunotherapy to earlier stages of the disease including adjuvant and first-line metastatic settings, and on inducing sensitivity to immune checkpoint inhibitor therapy through a combinatorial approach. Here, we review the contemporary understanding of the immune and molecular landscape in colorectal cancer and discuss ongoing clinical trials evaluating novel combination regimens based on immune checkpoint inhibitors.

Original languageEnglish (US)
Article number50
Issue number5
StatePublished - May 11 2017


  • Anti-PD1
  • Colon cancer
  • Immunotherapy

ASJC Scopus subject areas

  • Oncology
  • Cancer Research


Dive into the research topics of 'Immunotherapy for colorectal cancer'. Together they form a unique fingerprint.

Cite this